Bombay High Court Allows Writ Petitions Challenging Denial of Advance Authorization Benefits for Export of Pharmaceutical Products. Court holds that denial of benefits under Para 4.1.5 of Foreign Trade Policy on ground of non-fulfillment of condition of minimum value addition is unsustainable as the condition was not applicable to the product in question.
1 Aug 2016The petitioners, Sandoz Private Limited and Lupin Limited, are pharmaceutical companies engaged in the manufacture and export of pharmaceutical produc...




